VGI Health Technology Limited

NSX:VTL ISIN:AU0000152597

VGI Health Technology LimitedVGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

 
 
 

View in Other Languages

News

VGI Health Technology Limited (NSX:VTL) Update on Sale of Invictus BioPharma

🕔12/21/2022 4:05:00 PM 2382

On 5 April 2022, the Directors of VGI Health Technology Limited (NSX:VTL) announced the sale of its wholly owned subsidiary, Invictus BioPharma Pty Ltd to Invictus BioPharma Holdings Ltd (IVBHL) (the Transaction).

Read Full Article

VGI Health Technology Limited (NSX:VTL) R & D Facility Agreement with Fundsquire Pty Ltd

🕔10/13/2022 3:26:00 PM 1631

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has entered into an R&D Loan Facility Agreement (Loan Facility) with Fundsquire Pty Ltd.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH Phase II Clinical Study

🕔10/5/2022 8:58:00 AM 1709

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Receives Ethics Approval for US Clinical Study

🕔9/26/2022 8:54:00 AM 1894

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has received ethics approval to proceed with a US pharmacokinetics and exercise clinical study.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient

🕔9/14/2022 8:50:00 AM 1986

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).

Read Full Article

VGI Health Technology Limited (NSX:VTL) June 2022 Quarterly Update

🕔7/29/2022 8:57:00 AM 1860

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 June 2022.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Clinical Study Begins Recruitment of Patients

🕔7/5/2022 9:29:00 AM 2629

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has commenced recruitment of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic SteatoHepatitis.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Binding Sale Agreement of Subsidiary

🕔4/6/2022 8:50:00 AM 2763

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has today executed a binding agreement for the sale of its wholly owned subsidiary Invictus BioPharma Pty Ltd.

Read Full Article

VGI Health Technology Limited (NSX:VTL) US Divisional Patent to be Granted

🕔4/4/2022 7:44:00 AM 2592

VGI Health Technology Limited (NSX:VTL) is pleased to announce that the United States Patent and Trademarks Office (USPTO) intends to grant a divisional patent for the 'Transmucosal Delivery of Tocotrienols' to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd.

Read Full Article

VGI Health Technology Limited (NSX:VTL) to Present at American Society for Nutrition Conference

🕔3/21/2022 8:57:00 AM 3195

VGI Health Technology Limited (NSX:VTL) is pleased to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, will be presenting an abstract at the American Society for Nutrition (ASN) Annual Conference, Nutrition 2022.

Read Full Article
###

50,393 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 773) (Last 30 Days: 3316) (Since Published: 49592) 

Company Data

    Headquarters
  • Level 57, MLC Centre
    25 Martin Place
    Sydney, NSW, 2000
    Australia
  • Telephone
  • +61-2-8279-8908 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.vgiht.com

Company Reports

Quarterly Report